Key references: Intravenous iron supplementation

  • Bishay RH, Ganda K, Seibel MJ. Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature. Ther Adv Endocrinol Metab 2017;8(1-2):14-9. https://www.ncbi.nlm.nih.gov/pubmed/28203361
  • Blazevic A, Hunze J, Boots JM. Severe hypophosphataemia after intravenous iron administration. Neth J Med 2014;72(1):49-53. http://www.ncbi.nlm.nih.gov/pubmed/24457442
  • Canning M, Grannell L. A stain on iron therapy. Aust Prescr 2020;43(5):160-3. https://www.ncbi.nlm.nih.gov/pubmed/33093742
  • Detlie TE, Lindstrom JC, Jahnsen ME, Finnes E, Zoller H, Moum B, et al. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther 2019;50(4):397-406. https://www.ncbi.nlm.nih.gov/pubmed/31264261
  • Richards T, Breymann C, Brookes MJ, Lindgren S, Macdougall IC, McMahon LP, et al. Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice. Ann Med 2021;53(1):274-85. https://www.ncbi.nlm.nih.gov/pubmed/33426933
  • Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA 2020;323(5):432-43. https://www.ncbi.nlm.nih.gov/pubmed/32016310